Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.47 |
| ▸ | P4HB | P07237 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2165184 | 1.00 | RECQL (0.55) | RECQLMEN1KMT2ANPC1RAB9A | |
| SCHEMBL746312 | 1.00 | RECQL (0.55) | RECQLMEN1KMT2ANPC1RAB9A | |
| Methylamine SCHEMBL9389458 | 0.95 | RECQL (0.55) | RECQLMEN1KMT2ANPC1RAB9A | |
| SCHEMBL9218471 | 0.85 | GCGR (0.51) | RECQLMEN1KMT2ANPC1RAB9A | |
| SCHEMBL9218480 | 0.85 | GCGR (0.51) | RECQLMEN1KMT2ANPC1RAB9A | |
| SCHEMBL5215991 | 0.81 | RECQL (0.55) | RECQLMEN1KMT2ANPC1RAB9A | |
| SCHEMBL14088919 | 0.81 | MAPT (0.51) | RECQLMEN1KMT2ANPC1RAB9A | |
| SCHEMBL8274381 | 0.81 | MAPT (0.51) | RECQLMEN1KMT2ANPC1RAB9A | |
| SCHEMBL14904519 | 0.81 | NFE2L2 (0.54) | RECQLMEN1KMT2ANPC1RAB9A | |
| SCHEMBL5954099 | 0.81 | RECQL (0.55) | RECQLMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450271-B | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2024-09-20 | — | — | CN | disclosed |
| EP-4384013-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023073115-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4173485-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-03 | — | — | EP | disclosed |
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-4003965-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | Nurix Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450271-A | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021021761-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| EP-2927218-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| CN-107382892-A | A kind of preparation technology of the nitro isoxazole compound of 3 aryl 4 | 贵州大学 | 2017-11-24 | — | — | CN | disclosed |
| EP-1328534-A2 | 6-O-SUBSTITUTED ERYTHROMYCIN DERIVATIVES HAVING IMPROVED GASTROINTESTINAL TOLERANCE | Abbott Laboratories (US) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002032919-A2 | 6-O-SUBSTITUTED ERYTHROMYCIN DERIVATIVES HAVING IMPROVED GASTROINTESTINAL TOLERANCE | ABBOTT LABORATORIES (US) | 2002-04-25 | — | — | WO | disclosed |
| US-5314865-A | Certain alkylidine aminooxyamide compounds useful as herbicides | ICI AMERICAS INC. (US) | 1994-05-24 | — | — | US | disclosed |
| EP-0586393-A1 | SUBSTITUTED-2-PHENYL-3-METHOXYPROPENOATES AS FUNGICIDES | ZENECA LIMITED (GB) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992018487-A1 | SUBSTITUTED-2-PHENYL-3-METHOXYPROPENOATES AS FUNGICIDES | ZENECA LIMITED (GB) | 1992-10-29 | — | — | WO | disclosed |
| US-5002605-A | Herbicides | ICI AMERICAS INC. (US) | 1991-03-26 | — | — | US | disclosed |
| US-4261728-A | PREEMERGENT ACTIVITY | MONSANTO COMPANY (US) | 1981-04-14 | — | — | US | disclosed |
| US-4247322-A | HERBICIDE | MONSANTO COMPANY (US) | 1981-01-27 | — | — | US | disclosed |
| US-4187099-A | 3-Aryl-4-isothiazolecarboxylic acid and 3-aryl-4-isoxazolecarboxylic acid derivatives and their use as herbicides | MONSANTO COMPANY (US) | 1980-02-05 | — | — | US | disclosed |
| US-4144047-A | SOYBEANS | MONSANTO COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | CBLB, CBL, CBLC | RECQL 1401/4885MEN1 4354/4885KMT2A 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.